145 related articles for article (PubMed ID: 11088052)
1. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma.
Matsuyama M; Yamazaki O; Horii K; Higaki I; Kawai S; Mikami S; Higashino M; Oka H; Nakai T; Inoue T
J Surg Oncol; 2000 Nov; 75(3):197-202. PubMed ID: 11088052
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of erythropoietin in hepatocellular carcinoma.
Muta H; Funakoshi A; Baba T; Uike N; Wakasugi H; Kozuru M; Jimi A
Intern Med; 1994 Jul; 33(7):427-31. PubMed ID: 7524823
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence.
Sakisaka S; Watanabe M; Tateishi H; Harada M; Shakado S; Mimura Y; Gondo K; Yoshitake M; Noguchi K; Hino T
Hepatology; 1993 Dec; 18(6):1357-62. PubMed ID: 7694895
[TBL] [Abstract][Full Text] [Related]
4. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of erythrocytosis in patients with hepatocellular carcinoma.
Hwang SJ; Lee SD; Wu JC; Chang CF; Lu CL; Tsay SH; Lo KJ
Zhonghua Yi Xue Za Zhi (Taipei); 1994 May; 53(5):262-9. PubMed ID: 7518732
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
7. A resected case of metachronous liver metastasis from lung cancer producing alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II).
Oshiro Y; Takada Y; Enomoto T; Fukao K; Ishikawa S; Iijima T
Hepatogastroenterology; 2004; 51(58):1144-7. PubMed ID: 15239263
[TBL] [Abstract][Full Text] [Related]
8. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
9. [Erythrocytosis associated with hepatocellular carcinoma. Two case reports].
Argumanis E; Quispe D; Ruiz E
Rev Gastroenterol Peru; 2002; 22(1):84-7. PubMed ID: 11961573
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
11. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
13. [Erythrocytosis in patients with hepatocarcinoma in alcoholic cirrhosis: ectopic production of erythropoietin?].
Giovanardi P; Sacchetti C; Cameroni P; Grandi M
Recenti Prog Med; 1998 May; 89(5):250-2. PubMed ID: 9676132
[TBL] [Abstract][Full Text] [Related]
14. Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4α Expression.
Sun W; Kosyna FK; Jelkmann W; Depping R
Cell Physiol Biochem; 2015; 37(6):2257-64. PubMed ID: 26624507
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
17. Des-gamma carboxy prothrombin (PIVKA-II) and alpha-fetoprotein producing gastric cancer with multiple liver metastases.
Takahashi Y; Inoue T
Pathol Int; 2003 Apr; 53(4):236-40. PubMed ID: 12675768
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
